100 U.S. PATIENTS TREATED IN THE TWO-LEVEL IDE CLINICAL TRIAL OF THE SPINEART BAGUERA® C CERVICAL DISC PROSTHESIS
100 U.S. PATIENTS TREATED IN THE SINGLE LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS
LAGUNA HILLS, CA, April 21, 2022 – Spineart USA Inc. announced today that surgery has been performed on 100 patients in the single-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device in the U.S. designed to reconstruct the cervical disc following discectomy for symptomatic cervical disc disease.
Spineart is currently conducting, in parallel, a single-level and two-level IDE Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis at more than 20 sites in the U.S. The two-level study is also expected to hit the 100-patient benchmark in the coming month, bringing the total surgeries performed to more than 200.Descargar las noticias de prensa